Mizuho Maintains Buy on BridgeBio Pharma, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has maintained a 'Buy' rating on BridgeBio Pharma (NASDAQ:BBIO) and raised the price target from $50 to $60.
August 14, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has maintained a 'Buy' rating on BridgeBio Pharma and raised the price target from $50 to $60.
The 'Buy' rating maintained by Mizuho indicates a positive outlook for BridgeBio Pharma. The increase in price target from $50 to $60 suggests that the analyst expects the stock to perform well in the short term. This could potentially lead to an increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100